Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Cancer: A Multicenter Study

  • End date
    Nov 27, 2025
  • participants needed
  • sponsor
    Tianjin Medical University Second Hospital
Updated on 27 June 2022


This is a single-arm, open-label, multicenter clinical trial to investigate the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as perioperative treatment in patients with muscle-invasive bladder cancer (MIBC) prior to cystectomy or complete TURBT. Patients will receive perioperative treatment with tislelizumab in combination with nab-paclitaxel every 3 weeks for 3 treatment cycles over 9 weeks followed by radical cystectomy or complete TURBT.

Condition Muscle Invasive Bladder Cancer Urothelial Carcinoma
Treatment Tislelizumab Nab paclitaxel
Clinical Study IdentifierNCT05328336
SponsorTianjin Medical University Second Hospital
Last Modified on27 June 2022


Yes No Not Sure

Inclusion Criteria

Willing and able to provide written informed consent
Ability to comply with the protocol
Age ≥ 18 years
Suitable and planned for complete transurethral resection of bladder tumor or radical cystectomy
At least one measurable lesion meeting RECISTv1.1 criteria prior to transurethral bladder tumor electrosurgery (MR/CT long diameter of ≥10 mm or short diameter of ≥15 mm of enlarged lymph node required for this measurable lesion according to RECISTv1.1)
Histopathologically confirmed urothelial carcinoma. Patients with mixed histologies are required to have a dominant (i.e. 50% at least) urothelial cell pattern
Clinical stage T2-T4a NxM0 disease by CT (or MRI)
Expected survival time is greater than 12 weeks
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 1 or 2
Agree to provide tissue examination specimens (used to detect PD-L1 expression, tumor mutation burden, etc.)
The organ function level must meet the following requirements
Hematological indicators: absolute neutrophil count ≥1.5×10^9/ L, platelet count ≥80×10^9/L, hemoglobin ≥6.0 g/dL (can be maintained by symptomatic treatment)
Liver function: total bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase
≤ 2.5 times the upper limit of normal value, if there is intrahepatic
transaminase ≤ 5 times the upper limit of normal value
Renal function: creatinine ≤ 2 times the upper limit of normal, and creatinine clearance ≥ 30 ml/min

Exclusion Criteria

Receive live attenuated vaccines within 4 weeks before treatment or plan to receive live attenuated vaccines during the study period
Active, known or suspected autoimmune diseases
Known history of primary immunodeficiency
Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation
Female patients who are pregnant or breastfeeding
Untreated acute or chronic active hepatitis B or C infection. In the case of patients receiving antiviral therapy, the doctor will judge whether they are eligible for enrollment according to the individual conditions of the patient while monitoring the virus copy number
Have used immunosuppressive drugs in the past 4 weeks before starting treatment, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroids (that is, prednisolone or equivalent physiological doses of no more than 10 mg/day) Other corticosteroids)
Those who are known or suspected to be allergic to tislelizumab and nab paclitaxel
Have a clear history of active tuberculosis
Have received PD-1/PD-L1/CTLA-4 antibody or other immunotherapy in the past
Those who are participating in other clinical research
Reproductive men or women who are likely to become pregnant have not taken reliable contraceptive measures
Uncontrolled concurrent diseases include but are not limited to
HIV-infected persons (HIV antibody positive)
Serious infections that are active or poorly clinically controlled
There are serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [ie refers to After drug treatment, it is still greater than or equal to CTCAE Grade 2 hypertension]) evidence
Active bleeding or new thrombotic disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note